Evidence map›Paper›PMID 42310984›Full record

ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026

Dispensing of Antiemetics During Pregnancy in Aotearoa New Zealand, 2005-2020.

Sarah Donald, Katrina Sharples, Dave Barson, Karyn Maclennan, Leanne Te Karu, Diana Phone, Hedwig van Asten, Michael Stitely, Lianne Parkin

Abstract read
In one paragraph

Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah DonaldDepartment of Public Health - Dunedin, Faculty of Medicine, University of Otago - Ōtākou Whakaihu Waka, Dunedin, New Zealand.ORCID https://orcid.org/0000-0002-7189-3200
Katrina SharplesDepartment of Mathematics and Statistics, University of Otago - Ōtākou Whakaihu Waka, Dunedin, New Zealand.ORCID https://orcid.org/0000-0003-3821-789X
Dave BarsonDepartment of Public Health - Dunedin, Faculty of Medicine, University of Otago - Ōtākou Whakaihu Waka, Dunedin, New Zealand.ORCID https://orcid.org/0000-0003-1984-6690
Karyn MaclennanDepartment of Public Health - Dunedin, Faculty of Medicine, University of Otago - Ōtākou Whakaihu Waka, Dunedin, New Zealand.
Leanne Te KaruDepartment of General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand.
Diana PhoneTe Whatu Ora Waitematā, Auckland, New Zealand.
Hedwig van AstenTe Whatu Ora Southern, Dunedin, New Zealand.
Michael StitelyTe Whatu Ora Southern, Invercargill, New Zealand.ORCID https://orcid.org/0000-0001-6498-9725
Lianne ParkinDepartment of Public Health - Dunedin, Faculty of Medicine, University of Otago - Ōtākou Whakaihu Waka, Dunedin, New Zealand.ORCID https://orcid.org/0000-0002-6824-6176

Funding

Health Research Council of New Zealand 21/279/A
6 · The paper itself

Abstract

backgroundAntiemetic use during pregnancy is rising in high-income countries. Increasing use of antiemetics has also been documented in Aotearoa New Zealand (NZ); however, the specific antiemetics dispensed have not been reported.

aimTo describe patterns of antiemetic dispensing during pregnancy in NZ, 2005-2020. MATERIALS AND

methodsCommunity-based antiemetic dispensings were linked with 1.37 million pregnancies in the New Zealand Pregnancy Cohort. The proportions of pregnancies in which there was at least one dispensing of any and of specific antiemetics were calculated for each trimester and calendar year. Maternal characteristics and the sequence in which unique antiemetic regimens were introduced were described for pregnancies with first trimester exposure.

resultsFirst trimester antiemetic exposure increased from 4.1% to 19.7% of pregnancies between 2005 and 2019. Although metoclopramide was the most commonly dispensed antiemetic during Trimester 1 in all years (increasing from 3.1% to 12.4%), there was a substantial increase in ondansetron dispensing (0.1% to 9.1%). Ondansetron users were more likely than metoclopramide users to be European/Other and have a hospital admission for hyperemesis gravidarum. Metoclopramide and ondansetron monotherapy were first-line regimens in 70.0% and 1.9% of pregnancies with Trimester 1 exposure between 2005 and 2010 versus 46.5% and 26.5% between 2016 and 2020.

conclusionsOndansetron dispensing increased substantially over time. Further exploration of the context of ondansetron prescribing in NZ is warranted, as is further research into potential adverse outcomes.

Indexed as

AntiemeticsPractice Patterns, Physicians'Pregnancy ComplicationsAdultDicyclomineDomperidoneDoxylamineFemaleHumansMetoclopramideNew ZealandOndansetronPregnancyPregnancy Trimester, FirstPromethazineAntiemeticsDicyclomineDomperidoneDoxylamineMetoclopramideOndansetronPromethazine

Identifiers

PMID42310984
PMCPMC13276433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.